Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010;12(1):102.
doi: 10.1186/bcr2474. Epub 2010 Feb 3.

Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?

Rodney J Scott
Editorial

Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?

Rodney J Scott. Breast Cancer Res. 2010.

Abstract

Genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time and it is only now that insights have been gained into which polymorphisms are most likely to be important in determining not only disease likelihood but also outcome. The quest to be able to accurately predict patient outcomes in breast cancer may now be a step closer as increased sample size is leading to more robust statistical analysis and a better understanding of molecular mechanisms of disease are forthcoming.

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Schmidt Mk, Tommiska J, Broeks A, van Leeuwen FE, van't Veer LJ, Pharoah PDP, Easton DF, Shah M, Humphreys M, Dörk T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res. 2009;11:R89. doi: 10.1186/bcr2460. - DOI - PMC - PubMed
    1. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–365. doi: 10.1038/ng1093. - DOI - PubMed
    1. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang S-J, Strong LC, Lozano G, Levine AJ. A single nucleotide polypmorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602. doi: 10.1016/j.cell.2004.11.022. - DOI - PubMed
    1. Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I. The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health study. Cancer Causes Control. 2007;18:621–625. doi: 10.1007/s10552-007-9004-x. - DOI - PubMed
    1. Campbell IG, Eccles DM, Choon DYH. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 2006;240:195–197. doi: 10.1016/j.canlet.2005.09.003. - DOI - PubMed

Substances